In short
Gefitinib, also known as Iressa or ZD1839, is a targeted therapy drug being studied in clinical trials for various types of cancer. This article summarizes key information about Gefitinib's use in clinical trials, including its potential benefits, side effects, and effectiveness in treating different cancers such as lung cancer, head and neck cancer, and leukemia.
At a glance
- Drug Name
- Gefitinib (Iressa, ZD1839)
- Mechanism of Action
- Blocks epidermal growth factor receptor (EGFR) to inhibit cancer cell growth
- Administration
- Oral tablet, typically once daily
- Cancer Types Studied
- Non-small cell lung cancer, head and neck cancer, acute myelogenous leukemia, pancreatic cancer, hepatocellular carcinoma, esophageal cancer, mesothelioma
- Clinical Trial Phases
- Primarily Phase II studies
- Primary Outcomes
- Response rate, progression-free survival, overall survival
- Combination Therapies
- Studied with chemotherapy, radiotherapy, and other targeted therapies
- Patient Populations
- Includes both previously treated and untreated patients, various cancer stages
- Ongoing Research
- Efficacy in different cancer types, optimal dosing, combination strategies
What is Gefitinib?
Gefitinib, also known by its brand names Iressa or ZD1839, is a medication used in cancer treatment. It belongs to a class of drugs called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. These drugs work by targeting specific proteins on cancer cells to slow down or stop their growth.
How Gefitinib Works
Gefitinib works by blocking a protein called epidermal growth factor receptor (EGFR) on the surface of cancer cells. When EGFR is stimulated, it triggers a series of chemical reactions that tell the tumor to grow. By blocking EGFR, Gefitinib aims to stop these reactions and prevent the tumor from growing or spreading.
Conditions Treated with Gefitinib
Gefitinib has been studied and used in the treatment of various types of cancer, including:
- Non-small cell lung cancer (NSCLC): Gefitinib is approved by the FDA for treating advanced lung cancer, particularly in patients with specific genetic mutations in their EGFR gene.
- Head and neck cancer: Research is ongoing to evaluate Gefitinib's effectiveness in treating advanced head and neck cancers.
- Skin cancer: Studies have investigated the use of Gefitinib in treating recurrent or metastatic squamous cell carcinoma of the skin.
- Acute myelogenous leukemia: Research has explored the potential of Gefitinib in treating this type of blood cancer.
- Pancreatic cancer: Clinical trials have examined the combination of Gefitinib with other treatments for metastatic pancreatic cancer.
- Hepatocellular carcinoma (liver cancer): Studies have investigated Gefitinib as an adjuvant therapy (additional treatment after surgery) for patients with resectable liver cancer.
- Esophageal and gastroesophageal junction cancer: Research has explored the effectiveness of Gefitinib in treating recurrent or metastatic cancers in these areas.
How Gefitinib is Administered
Gefitinib is typically taken as an oral medication in the form of tablets. The dosage and duration of treatment can vary depending on the specific condition being treated and the individual patient's needs. Some common administration methods include:
- Daily dosing of 250 mg tablets.
- Higher doses of 500 mg or 750 mg daily in some studies.
- Continuous daily dosing without interruption.
It's important to note that Gefitinib should only be taken as prescribed by a healthcare professional, and patients should follow their doctor's instructions carefully.
Potential Side Effects
Like all medications, Gefitinib can cause side effects. While not everyone experiences side effects, it's important to be aware of potential issues. Common side effects may include:
- Skin rash or acne-like eruptions
- Diarrhea
- Nausea
- Loss of appetite
- Fatigue
More serious side effects, though less common, can include lung problems (such as interstitial lung disease) and liver problems. Patients should report any unusual symptoms or side effects to their healthcare provider promptly.
Ongoing Research and Clinical Trials
Researchers continue to study Gefitinib to better understand its effectiveness and potential applications in cancer treatment. Some areas of ongoing research include:
- Combining Gefitinib with other cancer treatments, such as chemotherapy or radiation therapy, to enhance its effectiveness.
- Using Gefitinib as an adjuvant therapy after surgery to prevent cancer recurrence.
- Exploring the use of Gefitinib in different types of cancer and at various stages of disease progression.
- Investigating biomarkers that may help predict which patients are most likely to benefit from Gefitinib treatment.
These ongoing studies aim to improve our understanding of Gefitinib and optimize its use in cancer treatment, potentially expanding its applications and benefits for patients in the future.